JAK2 and leukemia: Furthermore, combination therapies that combine JAK2 inhibitors with chemotherapy, immunotherapy, or epigenetic modulators may enhance the therapeutic effects by targeting multiple mechanisms of leukemia pathogenesis simultaneously[40,41].